TP53 and cancer: Moreover, the GSEA analysis further suggested that C1 and C2 subtypes significantly differed in gene set enrichment in immune cells (T cell receptor signaling pathway, antigen processing and presentation, natural killer cell-mediated cytotoxicity, B cell receptor signaling pathway, and leukocyte transendothelial migration) (Fig. 4F) and oncogenic pathways (VEGF signaling pathway, P53 signaling pathway, DNA replication, apoptosis, and pathways in cancer) (Fig. 4G).